The failure of a well-designed, randomized trial of granulocyte colony-stimulating factor (G-CSF) therapy to significantly improve cardiac function after acute myocardial infarction, despite substantial bone marrow cell mobilization, is reported by Engelmann et al. (1) in this issue of the Journal. In 44 revascularized subacute ST-segment elevation myocardial infarction (STEMI) patients, 5 days of G-CSF therapy resulted in a modest increase in ejection fraction (5% to 6%) without significant change in regional function in both subjects and controls, as assessed by magnetic resonance imaging at 3 months. The study seems to signal the end to an era that began just 5 years ago. In late 2001, 2 landmark publications (2,3) triggered a series of animal laboratory studies showing that stem cells could engraft in the damaged myocardium, decrease infarct size, improve myocardial perfusion and function, and decrease mortality (4 -7). The cells could be delivered by intramyocardial or intravenous injection and even indirectly by cytokine stimulation. The end of this era is almost equally dramatic; beyond small increases in ejection fraction and regional perfusion (8) , none of these strategies have produced similar outcomes in man. It seems we have run into a wall, and need to look around for a door; we need some great new ideas.
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Such ideas commonly evolve from a simple observation transformed by an intuitive leap to an entirely new concept. Thus, Johannes Kepler's astonishing leap to the laws of planetary motion from Tycho Brahe's decades-earlier recording of celestial data, the burrs stuck to a Swiss mountaineer's wool pants that lead to velcro, or Alexander Fleming's leap from a spoiled Petri dish to the discovery of penicillin. For cardiology's greatest idea, myocardial regeneration, in the past 5 years, 3 such intuitive leaps from a simple observation seem, as Daniel Quinn suggests in Beyond Civilization, "to see that which is so evident as to be unseeable," and to provide inspiration for a new generation of clinical testing (9) . An observation: injury to the opossum's pouch. The fetal opossum's pouch injured at day 9 heals without a scar with normal hair follicle growth and epithelial maturation. The same injury a few days later induces a permanent scar (10) . This fetal transition point in scarless healing, which occurs in many species, appears coincident with appearance of the inflammatory response. If ontogeny recapitulates phylogeny (i.e., growth of the organism parallels the evolution of species), then perhaps the essential elements of the nonscarring fetal environment could be re-created in an adult. Indeed, this year the Kerr laboratory made that intuitive leap in paralyzed rats by re-establishing spinal cord function with stem cells, using a strategy that "overcomes repulsive cues and/or provides attractive cues to stem cells" as occurs in embryonic growth. The critical factor turned out to be glial cell-derived neurotrophic factor (GDNF), which controls the development and survival of neurons in the mesencephalon; addition of GDNF to the stem cells resulted in restoration of hind limb function; in its absence paralysis persisted (11) .
The challenge for myocardial regeneration seems similar: to identify the factor(s) that might create this more hospitable fetal environment. Two classes of environmental modifiers, prominent in embryonic development, are probably essential: cytokines that promote migration and proliferation, and inhibitors of apoptotic cell death. In the developing heart, 2 such critical factors are thymosin ␤4 and Akt-1. At 4 weeks after coronary artery ligation in mice, treatment with thymosin ␤4 results in dramatic differences in ejection fraction (58% vs. 28%) (12) . This effect may be mediated through activation of Akt-1, which has the dual function of up-regulating expression of some familiar growth factors (vascular endothelial growth factor, fibroblast growth factor, insulin-like growth factor-1 [IGF-I], and hepatocyte growth factor [HGF]) and inhibiting apoptotic factors (Bcl-2 and caspases). In the rat infarct model, Akt-1 overexpression restores 80% to 90% of lost myocardial volume and completely normalizes systolic and diastolic cardiac function in a dose-dependent manner (13) . Remarkably, just the culture medium itself, when taken from Akt-overexpressing stem cells, significantly limits infarct size and improves ventricular function (14) . Clearly the cell's environment, ignored in the first era of clinical trials, seems critical for myocardial regeneration.
Appealing environment-modifying candidates from embryologic development are not limited to thymosin ␤-4 and Akt-1. Other growth factors like IGF-1 and HGF are both angiogenic and antiapoptotic and, in addition, induce expression of collagen-degrading metalloproteinases that create an extracellular matrix receptive to cell migration.
The method for creating a more hospitable cell environment is also open to innovation. For instance, stem cells can be induced to create their own more favorable environment by up-regulating specific genes. Mesenchymal stem cells pre-conditioned in a hypoxic environment up-regulate Akt expression (13) , and stem cells induced to overexpress HGF increase capillary density, reduce collagen content, and improve cardiac function in the rat infarct model (15) . In the upcoming era of clinical trials, this new idea, recapitulating ontogeny to create a cellular environment analogous to the opossum's pouch, seems certain to play a central role. An observation: Y-chromosomes in transplanted female hearts. In 2002, Quaini et al. (16) reported the interesting observation that proliferating Y-chromosome cells appeared in 7% to 10% of the myocytes and arterioles of female hearts that had been transplanted into human male recipients. The Anversa laboratory made the intuitive leap to the idea that these cells came from residual cardiac tissue of the recipient. Their search led to the discovery of previously unrecognized multipotent self-renewing cardiac stem cells clustered in interstitial niches of the atrium. Based on this discovery, they have proposed that the heart is a continually selfrenewing organ (17) . From this critical paradigm shift it is a short step to a major new idea in myocardial regeneration: use the heart's own stem cells. Indeed, in the rat infarct model, intra-aortic injection of cardiac stem cells decreased infarct size by 29%, with significantly higher fractional shortening, ejection fraction, and left ventricular systolic wall thickness compared with controls (18) . The problem of myocardial regeneration is hardly solved, however, because the regenerated myocytes were clustered together in foci surrounded by collagenous scar. Thus, although the cardiac stem cells engraft and improve cardiac performance, they do not induce a return to normal myocardial histology. A logical next step, testable in clinical trials, would seem to be merging the new idea of cardiac stem cells with the new idea of replicating the embryonic environment. An observation: a hole punched in a mouse's ear. In 1979, a new mouse line, termed MRL, was created for studies of autoimmunity. For identification purposes, a 2-mm hole was routinely punched in the mouse ear. These mice turned out to have an unanticipated, annoying characteristic: whereas normal mice retained the hole, the MRL mouse ear healed completely within a month. Twenty-two years later, Leferovich et al. (19) made the leap, freezeinfarcting a segment of the MRL heart. During the first week after injury, the injury site showed cardiomyocytes penetrating the wound site, and by day 60, the heart had healed with little to no scar. In the healed myocardium, fully 20% of these cells were actively proliferating. When Ychromosome-containing bone marrow cells were injected into lethally irradiated female recipients with no bone marrow cells, the majority of proliferating myocytes in the regenerated myocardium turned out to be of host origin. Clearly, one possibility is that the source of proliferating myocytes is the newly discovered host cardiac stem cell. An additional fascinating observation in the MRL mouse comes from differential gene expression studies. Matrix metalloproteinase, the enzyme that digests collagen, is strikingly overexpressed in the MRL mouse wound, again suggesting that in this animal the local environment may be more receptive to stem cell migration and proliferation.
The "scarless heart" response in the MRL mouse, thus far unique among mammals, is not, however, unique in the animal kingdom. The newt, the zebrafish, and some other amphibians are capable of regenerating limbs, spinal cord, and retina without scar. In 2002, Poss et al. (20) in the Keating laboratory demonstrated that zebrafish completely regenerate myocardium within 2 months after a 20% resection. The Keating laboratory's leap was to the idea that unique genes responsible for this response could be identified, and then used to induce scarless healing in other species that lacked this natural response. They identified such genes; they seem to control the formation of the initial mass of cells at the injury site, cell de-differentiation, and rapid cell cycle proliferation (21) . These data suggest an entirely different idea. The source of cells for cardiac regeneration might be mature cells at the injury site that de-differentiate, and then proliferate as myocytes and endothelial cells. This idea also is entirely consistent with the proliferation of host myocytes in the MRL mouse. Indeed, an extract derived from regenerating newt limbs does cause myotubes to de-differentiate (22) . The tantalizing prospect from this leap of reasoning is that if the proteins in this extract can be identified and used to induce similar changes in vivo, or if the responsible genes can be activated/ suppressed in mammals, the vision of myocardial regeneration in man might be realized.
Thus reading the G-CSF-STEMI (Granulocyte ColonyStimulating Factor ST-Segment Elevation Myocardial Infarction) trial results seems to provide us with a microcosm of modern times: 2 entirely divergent interpretations. Concerning myocardial regeneration, cynics may see this trial as marking an end to an era that began with a great vision in 2001, has had limited clinical success, and now confronts more uncertainties than anyone could have imagined 5 years ago. Yet the optimist may see in these same 5 years a new era founded on 3 fascinating intuitive leaps that allow us to see the unseeable, and that nature remains full of magical things just waiting for us to discover them.
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